You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 12, 2024

REGADENOSON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Regadenoson patents expire, and what generic alternatives are available?

Regadenoson is a drug marketed by Accord Hlthcare, Apotex, Baxter Hlthcare Corp, Dr Reddys, Eugia Pharma, Ge Healthcare, Gland Pharma Ltd, Hikma, Hospira, Ims Ltd, Indies Pharma, Meitheal, and Mylan. and is included in thirteen NDAs.

The generic ingredient in REGADENOSON is regadenoson. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the regadenoson profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Regadenoson

A generic version of REGADENOSON was approved as regadenoson by ACCORD HLTHCARE on April 11th, 2022.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for REGADENOSON?
  • What are the global sales for REGADENOSON?
  • What is Average Wholesale Price for REGADENOSON?
Drug patent expirations by year for REGADENOSON
Drug Prices for REGADENOSON

See drug prices for REGADENOSON

Recent Clinical Trials for REGADENOSON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
St. Jude Children's Research HospitalPhase 2
Emory UniversityN/A
Siemens Medical SolutionsN/A

See all REGADENOSON clinical trials

Pharmacology for REGADENOSON
Anatomical Therapeutic Chemical (ATC) Classes for REGADENOSON
Paragraph IV (Patent) Challenges for REGADENOSON
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LEXISCAN Injection regadenoson 0.08 mg/mL, 5 mL vial 022161 1 2012-04-10

US Patents and Regulatory Information for REGADENOSON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare REGADENOSON regadenoson SOLUTION;INTRAVENOUS 213236-001 Apr 11, 2022 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Gland Pharma Ltd REGADENOSON regadenoson SOLUTION;INTRAVENOUS 207320-001 Jul 12, 2022 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys REGADENOSON regadenoson SOLUTION;INTRAVENOUS 213210-001 Apr 11, 2022 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Meitheal REGADENOSON regadenoson SOLUTION;INTRAVENOUS 212806-001 Apr 11, 2022 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma REGADENOSON regadenoson SOLUTION;INTRAVENOUS 215827-001 Feb 2, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for REGADENOSON

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
GE Healthcare ASĀ  Rapiscan regadenoson EMEA/H/C/001176
This medicinal product is for diagnostic use only.Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
Authorised no no no 2010-09-06
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.